In relapsed CLL, ZYDELIG is used in combination with Rituxan® (rituximab) when CLL comes back after prior cancer treatment and when Rituxan treatment alone may be used due to other health problems. ZYDELIG should not be used as the first medicine to treat people who have been diagnosed with CLL.
Although CLL is not curable, your doctor can use different therapies or combinations of therapies to slow the growth of your CLL cells and provide you with periods of remission. The ultimate goal of therapy is to help you live longer without your disease getting worse.2
ZYDELIG works differently from chemotherapy because it blocks a specific protein in B cells called PI3K delta. PI3K delta sends signals to cancerous B cells telling them to multiply and helping them survive. ZYDELIG blocks these signals, helping to slow the growth of leukemia cells.3,4
Your white blood cell count might go up when you begin treatment with ZYDELIG. Keep in mind the increased count doesn’t mean that your ZYDELIG treatment isn’t working or that your disease is getting worse. In most cases, this initial rise in white blood cell count decreases over time while you’re taking ZYDELIG.2
At least 50% had been treated with 3 or more prior therapies.
The main goal, or primary endpoint, of the study was to measure how long people lived without their cancer getting worse while on treatment—also called progression-free survival. In the study, people taking ZYDELIG plus Rituxan had longer progression-free survival (19.4 months) than those taking Rituxan alone (6.5 months).4 In addition, 66% of those treated with ZYDELIG plus Rituxan experienced no disease progression at 1 year vs 13% of those treated with Rituxan alone.5
The safety profile of ZYDELIG has also been established in people with relapsed CLL.View the safety profile